Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
CureVac GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'CureVac GmbH - Product Pipeline Review - 2014', provides an overview of the CureVac GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CureVac GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CureVac GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CureVac GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CureVac GmbH's pipeline products Reasons to buy - Evaluate CureVac GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CureVac GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CureVac GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CureVac GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CureVac GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CureVac GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 CureVac GmbH Snapshot 5 CureVac GmbH Overview 5 Key Information 5 Key Facts 5 CureVac GmbH - Research and Development Overview 6 Key Therapeutic Areas 6 CureVac GmbH - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 CureVac GmbH - Pipeline Products Glance 12 CureVac GmbH - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 CureVac GmbH - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 CureVac GmbH - Drug Profiles 16 CV-9103 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CV-9104 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CV-9201 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CV-7201 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CV-8102 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Oligonucleotide for Cancer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Pandemic Influenza Vaccine (H1N1) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 rotavirus vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CureVac GmbH - Pipeline Analysis 25 CureVac GmbH - Pipeline Products by Target 25 CureVac GmbH - Pipeline Products by Route of Administration 26 CureVac GmbH - Pipeline Products by Molecule Type 27 CureVac GmbH - Recent Pipeline Updates 28 CureVac GmbH - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables CureVac GmbH, Key Information 5 CureVac GmbH, Key Facts 5 CureVac GmbH - Pipeline by Indication, 2014 7 CureVac GmbH - Pipeline by Stage of Development, 2014 8 CureVac GmbH - Monotherapy Products in Pipeline, 2014 9 CureVac GmbH - Out-Licensed Products in Pipeline, 2014 10 CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 CureVac GmbH - Phase II, 2014 12 CureVac GmbH - Phase I, 2014 13 CureVac GmbH - Preclinical, 2014 14 CureVac GmbH - Discovery, 2014 15 CureVac GmbH - Pipeline by Target, 2014 25 CureVac GmbH - Pipeline by Route of Administration, 2014 26 CureVac GmbH - Pipeline by Molecule Type, 2014 27 CureVac GmbH - Recent Pipeline Updates, 2014 28 CureVac GmbH, Other Locations 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.